NIH-funded research R01 grant

Understanding why some brain cells are more vulnerable in frontotemporal dementia

Official title: Cell Type and Regional Vulnerability in Frontotemporal Dementia

Funded at Regenerative Research Foundation · NIH-10795733 · Data updated 2026-11-12

This study is looking at why some brain cells are more affected by frontotemporal dementia than others, especially in people with certain gene mutations, and it aims to find ways to protect those vulnerable cells from damage.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionRegenerative Research Foundation
NIH-funded
Lab location1 site (Albany, UNITED STATES)
Project startAugust 1, 2021
Project endJuly 31, 2026
Funding year2024
Award (this year)$663,462
NIH project number4R01NS123568-02
Project IDNIH-10795733 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates for this research include individuals with familial frontotemporal dementia linked to MAPT gene mutations.

Less likely to help

Patients without MAPT gene mutations or those with other forms of dementia may not benefit from this research.

What this research studies

This research investigates the reasons behind the differential vulnerability of brain cell populations in frontotemporal dementia, particularly focusing on mutations in the MAPT gene that encodes the Tau protein. By analyzing induced pluripotent stem cells (iPSCs) derived from patients with familial dementia, the study aims to uncover how specific mutations lead to significant degeneration in certain brain regions while sparing others. The researchers will explore the connectivity between affected and unaffected areas to understand the mechanisms of tau spread and its impact on neural health. Ultimately, the goal is to develop therapies that can protect vulnerable neural cells from degeneration associated with tauopathies.

Why it matters

Potential benefit: If successful, this research could lead to new therapies that protect brain cells from degeneration in frontotemporal dementia.

How similar studies have gone: Previous research has shown promising results in understanding tauopathies, but this specific approach focusing on differential cell vulnerability is relatively novel.

Where this research is happening

  • Regenerative Research Foundation
    Albany, United States
    Active

Researchers

  • Principal investigator: Temple, Sally — Regenerative Research Foundation
  • Study coordinator: Temple, Sally

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.